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Objectives: From 2006 – 2013 the FDA approved 207 new molecular entities 
(NMEs), which included 84 efficacy statements supported by PRO assessments. In 
addition to NMEs, many previously-approved product labels were updated with 
PRO statements during this period. The purpose of this research was to review 
the efficacy claims supported by PROs to identify trends amongst the approved 
indications and differences between approved claims before and after finaliza-
tion of the guidance. MethOds: NME labels approved by the FDA from 2006 – 
2013 were reviewed on the Drugs@FDA website; updated labels were discovered 
via literature and Internet searches. An assessment or statement of efficacy was 
considered to be PRO-based if it assessed symptoms, side effects, or impacts on 
functioning and daily activities, entirely from the patient perspective. Results: 
From 2006 – 2013, the FDA approved an average of 25.9 NMEs per year. The aver-
age number of PROs included in NME labels from 2006 – 2010 was 14.2 per year 
(n = 71). From 2011 – 2013, the average was 4.3 PROs approved per year (n = 13). 
The difference between these two periods is statistically significant (t = 4.85, p = 
.002). Further investigation revealed 22 non-NME labels with PROs newly approved 
during this period, with no notable per-year trends. cOnclusiOns: The FDA’s 
PRO Guidance may not be the lone cause for the reduction of approved PROs in 
NME labels, but there was a significant drop in the number of approvals following 
its finalization. While the number of PROs approved in 2010 was similar to the 
numbers approved 2006 – 2009, submissions reviewed in 2010 may not have been 
asked to meet the standards of the PRO Guidance, thus impacting our analysis. 
Inclusion of non-NME labels approved from 2006 – 2013 does not increase the 
percentage of PROs approved.
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Objectives: To evaluate effect of side effect characteristics (frequency and sever-
ity) and stylistic factors (plain language or plain language combined with numeric 
frequency) on risk perception of side effects. MethOds: About 100 participants 
were randomly presented with four of eight conditions with information about 
medication side effects in a 2 (side effect frequency: low, high) X 2 (side effect 
severity: mild, severe) X 2 (communication style: plain language, plain language 
combined with numeric frequency) experimental design. The participants were 
then asked to rate their risk perception with each of the four conditions. Test for 
analysis of variance was performed. Results: As compared to plain language only, 
the use of combination of plain language and numeric frequencies to communicate 
side effect information lead to an increase in risk perception for mild side effects of 
high frequency (difference between mean risk perception scores = 25.30, p< 0.001). 
The mean risk perception scores did not differ significantly across the two com-
munication styles for severe side effects of high frequency, severe side effects of 
low frequency and mild side effects of low frequency. With plain language com-
munication style the difference between mean risk perception scores across two 
frequency levels was 42.68 (p< 0.001) for mild side effects whereas that for severe 
side effects was 61.59 (p< 0.001). Similar effects were seen with combination com-
munication style (mild side effects: difference between means= 70.34, p< 0.001; 
severe side effects: difference between means= 70.07, p< 0.001). With communica-
tion style and frequency kept constant, change in severity did not have any effect 
on the risk perception scores. cOnclusiOns: Frequency of side effects play a major 
role in evaluation of personal risk of side effects. Stylistic factors also affect risk 
perceptions to some extent based on the effects of frequency. These results may 
help health care providers in utilization of appropriate methods for communicating 
risk of medication side effects.
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Objectives: Adverse drug problems (ADPs) have caused significant morbidity 
and mortality to patients. The objective of this study was to develop a medication-
problem coping scale (MPCS) to measure patients’ coping responses to their ADP 
and calibrate the developed items using one-parameter logistic (1PL) and two-
parameter logistic (2PL) models. MethOds: A comprehensive literature review 
was conducted to identify candidate items to measure patient’s coping strategies 
when dealing with perceived ADPs. Supplementary items were then added to fill 
in the content gaps. The items were administered to patients in the community 
pharmacies which are incorporated into the Minnesota practice-based research 
network (PBRN). After collecting data from 140 patients, eleven items which met 
the assumptions of item response theory were calibrated using the 1PL and 2PL 
models respectively to determine which model is favored. Results: The 1PL and 
2PL model were compared by taking goodness-of-fit statistics, reliability of the 
estimated person scores, and standard error of measurement (SEM) into account. 
First, the chi-squared difference test was highly significant (X2(41.61, 10), P< 0.0001) 
indicating that the 2PL model provided a better fit to the item responses com-
pared to the 1PL model. This result was supported by the information-theoretic 
fit index (AIC) and the RMSEA value, all of which favored the 2PL model. In addi-
tion, the 2PL model was preferred with a higher value of score reliability esti-
mate (0.82) compared to that of the 1PL model (0.79). Finally, the 2PL model had 
much more information and much lower SEM over most of the coping behavior 
range. cOnclusiOns: Our findings indicated that the 2PL model was preferred 
than the 1PL model. It suggests that the 2PL model be used to obtain item param-
eters and to assess information function.
Indonesia Demographic and Health Survey data of 2007 was obtained from Measured 
DHS using a randomized subset of 1,470 observations. Multinomial and binomial 
logistic regression were performed to assess assocations between long-term, short-
term and no contraception with wife’s age, wife’s education, husband’s education, 
number of children ever born, wife’s religion, wife’s working status, husband’s occupa-
tion, and wealth index. Results: Wife’s education, wealth index, number of children 
ever born, and wife’s age were statistically significant at the 95% CL. Overall, account-
ing for all categorical levels of wife’s education and wealth index both were statisti-
cally significant while the difference between each category were not statistically 
significant. The wife’s education at a secondary level (OR: 2.05; 95% CL, 1.26-3.35 ) was 
the most likely to choose any contraception (short or long term) while the wife with 
a wealth index (OR: 1.73; 95% CL, 1.24-2.42) at the third quintile was the most likely 
to choose any contraception (short or long term). Within contraception categories 
(short or long term), the wife with a higher education or in the top quintile of the 
wealth index was the most likely to choose short-term contraception. For long-term 
contraception, the wife with a secondary education and in the third quintile of wealth 
were more likely to choose that method. cOnclusiOns: Wife’s education and wealth 
index indicate contraceptive choice. Between short-term and long-term contraceptive 
choice, wife’s education and wealth index increases are indicative for short-term but 
not for long-term warranting analysis of other socio-economic factors in association.
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Objectives: To ascertain the frequency and types of PRO violations made in US 
pharmaceutical promotional materials between 2006 and 2012 and determine if 
there were increases in violation warnings following issuance of the FDA draft and 
final PRO guidance. MethOds: Warning letters or notices of violation issued by the 
FDA’s Office of Prescription Drug Promotion (OPDP) were reviewed for PRO violations 
(n= 213). Type of violation was classified as: (1) PRO not fit for purpose; (2) Study 
design/Interpretation of results; (3) Statistical analysis; and/or (4) No Treatment 
benefit. Results: Of the 213 letters reviewed, 19% contained a PRO violation (n= 41); 
15 (37%) were warning letters and 26 (63%) were notice of violation letters. The 
most common violation was PRO not fit for purpose (54%) e.g. use of individual 
items (45%), content validity (36%), and broadening of the claim beyond what the 
PRO measures (27%). Issues with Study design/Interpretation of results were also 
high (49%), particularly broadening of claim beyond what was measured in the trial 
(55%), and no PRO used (50%). Fewer WLs/NOVs specified statistical issues (24%) but, 
most were because of lack of pre-specification of the analyses conducted (50%). 
Over half of the violations fell into more than one category (54%). PRO violations 
were issued across a wide array of therapeutic areas; pain drugs had the highest 
frequency (24%). Violations primarily occurred in professional sales and detail aids 
(22%), brochures (14%) and videos (11%). cOnclusiOns: A fifth of letters issued to 
companies contained PRO violations with most of this related to poor selection of 
the PRO measure used or trying to broaden the claim. More guidance from OPDP 
about what is considered ‘substantial evidence’ in this area could help reduce the 
number of letters issued.
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Objectives: The objective of this study was to determine if any discernible differ-
ences, in quantity or content, exist in feedback from male and female subjects dur-
ing cognitive debriefing interviews of translated patient questionnaires. MethOds: 
Cognitive debriefing took place with subjects diagnosed with Ulcerative Colitis, 
Stroke, COPD and Diabetes, across 54 different languages. Comments were clas-
sified as either those resulting in a translation revision made to improve compre-
hensibility, cultural appropriateness or grammar, or those leading to no revision, 
due to a stylistic suggestion or a source text deviation. The average number of 
comments made per subject was calculated for each classification, as well as a 
p value for the total using a two tailed t test. Results: Out of the total sample 
(n= 351), 171 respondents were male and 180 were female. The average number of 
comments made was 3.05 per male subject and 4.22 per female subject, with a p 
value of 0.006. For comments that resulted in a translation revision, per question-
naire, males averaged 0.95 comments and females averaged 1.19 comments, with a 
p value of 0.16. For comments that resulted in no revision, per questionnaire, males 
averaged 1.62 comments and females averaged 2.44 comments, with a p value of 
0.02. cOnclusiOns: The results show that females, overall, make more comments 
during cognitive debriefing interviews than men. Additionally, females tend to make 
more comments that do not result in a translation revision, which may be stylistic 
or source deviation comments. For comments that result in a translation revision, 
there is no meaningful difference between males and females as demonstrated by 
the marginal difference between the two means and the p value. Both males and 
females contribute equally to ensuring a final translation is culturally appropriate 
and comprehensible.
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